Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L.

Nat Cell Biol. 1999 May;1(1):60-7.

PMID:
10559866
2.

Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta.

Takizawa CG, Weis K, Morgan DO.

Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7938-43.

3.

Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.

Marko D, Romanakis K, Zankl H, Fürstenberger G, Steinbauer B, Eisenbrand G.

Cell Biochem Biophys. 1998;28(2-3):75-101.

PMID:
9515161
4.

Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.

Abraham RT, Acquarone M, Andersen A, Asensi A, Bellé R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, et al.

Biol Cell. 1995;83(2-3):105-20.

PMID:
7549905
5.

New colorimetric cytotoxicity assay for anticancer-drug screening.

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR.

J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12.

PMID:
2359136

Supplemental Content

Support Center